Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) CEO Sells $474,140.25 in Stock

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) CEO Brian Goff sold 11,091 shares of the business’s stock in a transaction on Thursday, August 8th. The stock was sold at an average price of $42.75, for a total value of $474,140.25. Following the completion of the sale, the chief executive officer now directly owns 78,792 shares in the company, valued at $3,368,358. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Agios Pharmaceuticals Stock Up 0.8 %

Shares of NASDAQ AGIO opened at $45.11 on Wednesday. The firm’s 50-day moving average price is $45.12 and its 200-day moving average price is $35.71. Agios Pharmaceuticals, Inc. has a 52-week low of $19.80 and a 52-week high of $50.35. The company has a market cap of $2.56 billion, a PE ratio of -7.14 and a beta of 0.79.

Agios Pharmaceuticals (NASDAQ:AGIO) last posted its earnings results on Thursday, August 1st. The biopharmaceutical company reported ($1.69) EPS for the quarter, missing analysts’ consensus estimates of ($1.60) by ($0.09). The company had revenue of $8.60 million during the quarter, compared to the consensus estimate of $9.34 million. Agios Pharmaceuticals had a negative return on equity of 44.84% and a negative net margin of 1,165.69%. The company’s revenue for the quarter was up 28.4% on a year-over-year basis. During the same period last year, the firm posted ($1.51) EPS. As a group, equities research analysts anticipate that Agios Pharmaceuticals, Inc. will post -2.15 EPS for the current fiscal year.

Institutional Trading of Agios Pharmaceuticals

A number of hedge funds have recently bought and sold shares of AGIO. Mirae Asset Global Investments Co. Ltd. boosted its position in Agios Pharmaceuticals by 0.8% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 39,248 shares of the biopharmaceutical company’s stock worth $1,148,000 after purchasing an additional 314 shares during the last quarter. CANADA LIFE ASSURANCE Co lifted its stake in shares of Agios Pharmaceuticals by 1.8% in the 1st quarter. CANADA LIFE ASSURANCE Co now owns 31,144 shares of the biopharmaceutical company’s stock worth $911,000 after purchasing an additional 540 shares during the period. Acadian Asset Management LLC purchased a new position in shares of Agios Pharmaceuticals in the second quarter worth approximately $37,000. Quest Partners LLC bought a new stake in Agios Pharmaceuticals during the second quarter valued at approximately $40,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its position in Agios Pharmaceuticals by 9.0% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 11,444 shares of the biopharmaceutical company’s stock valued at $255,000 after buying an additional 942 shares during the period.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on the company. JPMorgan Chase & Co. reaffirmed a “neutral” rating and issued a $46.00 price target on shares of Agios Pharmaceuticals in a research report on Thursday, June 13th. StockNews.com cut shares of Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Monday, August 5th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Agios Pharmaceuticals in a report on Monday, June 17th. The Goldman Sachs Group boosted their price objective on shares of Agios Pharmaceuticals from $33.00 to $53.00 and gave the stock a “neutral” rating in a report on Tuesday, June 4th. Finally, Royal Bank of Canada increased their target price on Agios Pharmaceuticals from $53.00 to $55.00 and gave the company an “outperform” rating in a research note on Friday, August 2nd. One analyst has rated the stock with a sell rating, two have assigned a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $51.33.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.